Background: Positive expression of estrogen receptor (ER) beta is correlated with a
favorable prognosis for patients with epidermal growth factor receptor (EGFR) mutations and …

The present study assessed whether estrogen receptor (ER) β1 is associated with the
survival of patients with advanced lung adenocarcinoma, with or without mutations of the …

There is growing evidence that estrogen receptors (ER) are expressed in lung cancer cells,
and are able to interact with the epidermal growth factor receptor (EGFR) signaling pathway …

PURPOSE: Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (EGFR–TKI)
demonstrates a dramatic clinical response for the lung adenocarcinoma patients harboring a …

Epidermal growth factor receptor (EGFR) mutations are more common in non‑small cell lung
cancer (NSCLC) and in female patients of East Asian origin. Therefore, the present study …

Introduction Unlike common EGFR mutations, many less common EGFR mutations remain
poorly characterized in terms of oncogenic function and drug sensitivity. Here, we …

To clarify the pathogenic and biological significance of EGFR mutations in lung cancer, we
compared the status of ERBB family receptors, their downstream signal transductions and …

Background/Aim: Acquired resistance to epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) has posed serious clinical problems in the treatment of lung …

Abstract Effects of estrogen receptorβ (ERβ) localization on epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) in advanced non-small cell lung cancer (NSCLC) are …

Estrogen receptor β (ER β) can regulate cellular signaling through non-genomic
mechanisms, potentially promoting resistance to epidermal growth factor receptor (EGFR) …